Aspirin also known as acetylsalicylic acid is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet, or "anti-clotting", effect and is used in long-term, low doses to prevent heart attacks, strokes and blood clot formation in people at high risk for developing blood clots. It has also been established that low doses of aspirin may be given immediately after a heart attack to reduce the risk of another heart attack or of the death of cardiac tissue.
When it comes to preventing blood clots after a knee replacement, good old aspirin may be just as effective as newer, more expensive drugs.
Studies in mice have demonstrated that obesity-induced inflammation contributes to the risk of colorectal cancer, but evidence in humans has been scarce.
Taking a low-dose aspirin daily may help women lower their risk of developing ovarian cancer. A new study co-led by Moffitt Cancer Center found that women who reported taking a low-dose aspirin every day had a 23 percent lower risk of ovarian cancer compared to nonaspirin users.
New research by Cardiff University has demonstrated a role for Aspirin in the treatment of bowel, prostate and breast cancer.
The ASPREE trial of more than 19,000 participants in Australia and the US is the largest and most comprehensive study to look at whether the many millions of older people around the world who take (100mg) low dose aspirin to preserve good health are deriving any benefit by doing so.
In a large clinical trial to determine the risks and benefits of daily low-dose aspirin in healthy older adults without previous cardiovascular events, aspirin did not prolong healthy, independent living (life free of dementia or persistent physical disability).
A large study led by Australian researchers has found that taking Aspirin tablets regularly to does not really prolong life or reduce the risk of a first heart attack or stroke.
AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration has approved LUMOXITI (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
Resistant hypertension affects 12 percent to15 percent of patients treated for high blood pressure according to a new scientific statement from the American Heart Association.
Platelet inhibition with aspirin is the cornerstone of medical therapy for coronary artery disease. In the era of percutaneous coronary intervention with drug-eluting stents, dual anti-platelet therapy with the addition of clopidogrel became the mainstay of therapy.
According to a new report from the Centers for Disease Control and Prevention (CDC), the efforts to prevent heart attacks and strokes in the United States have reached a plateau and are not making any further progress.
Bleeding in patients treated with anticoagulants should stimulate a search for cancer, according to late breaking results from the COMPASS trial presented today at ESC Congress 2018.
Combined oral anticoagulant and antiplatelet therapy is associated with a worse prognosis than anticoagulation alone in newly diagnosed atrial fibrillation patients without a clear indication for antiplatelets, according to late breaking results from the GARFIELD-AF registry presented today at ESC Congress 2018.
The role of aspirin in preventing a first heart attack or stroke among people at moderate risk of heart disease remains unclear.
Low dose Aspirin has been advocated to reduce the risk of a second heart attack or a stroke or other heart problems in persons who have had one episode. A major new study published in the Lancet, has found that taking Aspirin to prevent the first heart attack fails to work. In fact the risks of taking low dose Aspirin to prevent the first heart attack outweigh the benefits.
Long-term antiplatelet monotherapy after stenting is safe but does not reduce the risk of death or heart attack compared to standard dual antiplatelet therapy, according to late breaking results from the GLOBAL LEADERS trial presented today in a Hot Line Session at ESC Congress 2018 and published in The Lancet.
The antithrombin drug rivaroxaban does not reduce the risk of a composite endpoint of survival, myocardial infarction and stroke after an episode of worsening heart failure in patients with heart failure, sinus rhythm, and coronary artery disease, according to late breaking results from the COMMANDER HF trial presented today in a Hot Line Session at ESC Congress 2018 and with simultaneous publication in NEJM.
Patients with cardiovascular disease who develop major internal bleeding are much more likely to be diagnosed with cancer, a large international clinical trial has found.
Aspirin prevented serious vascular events in patients with diabetes who did not already have cardiovascular disease, but it caused almost as many major bleeds and there was no effect on cancers.
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to lower their risk, according to late breaking results from the ARRIVE study presented today in a Hot Line Session at ESC Congress 2018 and with simultaneous publication in the Lancet.